\*required for saving

|  |
| --- |
| **Patient Information** |
| Facility ID: | Event ID #: |
| \*Patient ID: | Social Security #: |
| Secondary ID #: | Medicare #: |
| Patient Name, Last: | First: | Middle: |
| \*Sex: F-Female M-Male  | \*Date of Birth: |
|  |  |
| Race (Select all that apply): American Indian or Alaska NativeAsianBlack or African AmericanMiddle Eastern or North AfricanNative Hawaiian or Pacific IslanderWhiteUnknownDeclined to respondEthnicity:Hispanic or LatinoNot Hispanic or LatinoUnknownDeclined to respond |  |
| **Event Information** |
| \*Event Type: DE – Dialysis Event | \*Date of Event: | \*Location: |
| \*Was the patient admitted/readmitted to the dialysis facility on this dialysis event date? **□** Yes **□** No |
| \*Transient Patient | **□** Yes | **□** No |
| **Risk Factors** |
|  |
| \*All Vascular Access Types Present: (check all that apply)  | Access placement date (mm/yyyy): |
| **□** Fistula  | \_\_\_\_\_ /\_\_\_\_\_\_\_\_\_ | **□** Unknown  |
| Buttonhole? | **□** Yes **□** No |  |
| **□** Graft | \_\_\_\_\_ /\_\_\_\_\_\_\_\_\_ | **□** Unknown |
| **□** Tunneled central line | \_\_\_\_\_ /\_\_\_\_\_\_\_\_\_ | **□** Unknown |
| **□** Non-tunneled central line | \_\_\_\_\_ /\_\_\_\_\_\_\_\_\_ | **□** Unknown |
| **□** Other vascular access device  | \_\_\_\_\_ /\_\_\_\_\_\_\_\_\_ | **□** Unknown |
| Is this a catheter-graft hybrid? **□** Yes **□** No  |  |
| Vascular access comment: \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_ |
| \*Access **used for dialysis at the time of the event**: (if more than one access was used for the dialysis treatment, please **indicate the access with the higher risk of infection**) |
|  **□** Fistula | **□** Non-tunneled central line |
|  **□** Graft | **□** Other vascular access device |
|  **□** Tunneled central line | **□** Catheter-Graft hybrid |
|  |
| **Event Details** |
|  |
| \*Specify Dialysis Event: (check at least one) |
| **□** **IV antimicrobial start**  | \*Date of IV antimicrobial start: \_\_\_\_\_ |
| \*Was vancomycin the antimicrobial used for this start? **□** Yes **□** No |
| \*Was this a new outpatient dialysis facility start or a continuation of a course initiated outside of the dialysis facility? |
| **□** New antimicrobial start | **□** Continuation of antimicrobial |
|  \*If new antimicrobial start, was a blood sample collected for culture? **□** Yes **□** No |
|  |
| **□** **Positive blood culture**  | \*Date of Positive blood culture: \_\_\_\_\_ |
| (\*specify organism and antimicrobial susceptibilities on pages 2-3) |
|  |
| \* What is the suspected source of the organism or organisms identified on the positive blood culture? (check one): |
| **□** Vascular access | **□** A source other than the vascular access | **□** Contamination | **□** Uncertain |
| \*Where was this positive blood culture collected?  |
| **□** Dialysis clinic  | **□** Hospital *(on the day of or the day following admission)* or E.D. | **□** Other location |
|  |
| **□** **Pus, redness, or increased swelling at vascular access site**  | \*Date of pus, redness, and increased swelling: \_\_\_\_\_ |
|  \*Check the access site(s) with pus, redness, or increased swelling: |
| **□** Fistula | **□** Graft**□** Catheter-Graft Hybrid | **□** Tunneled central line | **□** Non-tunneled central line | **□** Other vascular access device |
|  |
| \*Specify Problem(s): (check one or more) |
| **□** Fever ≥ 37.8°C (100°F) oral | **□** Chills or rigors | **□** Drop in blood pressure |
| **□** Wound (NOT related to vascular access) with pus or increased redness | **□** Urinary tract infection |
| **□** Cellulitis (skin redness, heat, or pain without open wound) | **□** Pneumonia or respiratory infection |
| **□** Other problem (specify): \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_ | **□** None |
|  |
| \*Specify Outcomes: | Loss of vascular access | **□** Yes | **□** No | **□** Unknown |
|  | Hospitalization | **□** Yes | **□** No | **□** Unknown |
|  | Death | **□** Yes | **□** No | **□** Unknown |
|  |
| Assurance of Confidentiality:  The voluntarily provided information obtained in this surveillance system that would permit identification of any individual or institution is collected with a guarantee that it will be held in strict confidence, will be used only for the purposes stated, and will not otherwise be disclosed or released without the consent of the individual, or the institution in accordance with Sections 304, 306 and 308(d) of the Public Health Service Act (42 USC 242b, 242k, and 242m(d)).Public reporting burden of this collection of information is estimated to average 50 minutes per response, including the time for reviewing instructions, searching existing data sources, gathering, and maintaining the data needed, and completing and reviewing the collection of information.  An agency may not conduct or sponsor, and a person is not required to respond to a collection of information unless it displays a currently valid OMB control number.  Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to CDC, Reports Clearance Officer, 1600 Clifton Rd., MS H21-8, Atlanta, GA 30333, ATTN:  PRA (0920-0666). CDC 57.502 (Front) Rev 10, v8.6 |

|  |
| --- |
| Pathogen # | **Gram-positive Organisms** |
| \_\_\_\_\_\_\_ | *Staphylococcus* coagulase-negative  | **VANC CEFOX/OX**S I R N S R N |
| (specify species if available): \_\_\_\_\_\_\_\_\_\_\_\_ |
| \_\_\_\_\_\_ | *\_\_\_\_Enterococcus faecium**\_\_\_\_Enterococcus faecalis**\_\_\_\_Enterococcus* spp.  (Only those not identified to the species level)  | **DAPTO**S S-DD NS N | **GENTHL§**S R N | **LNZ**S I R N | **VANC**S I R N |  |
| \_\_\_\_\_\_\_ | *Staphylococcus aureus* | **CIPRO/LEVO/MOXI**S I R N | **CLIND**S I R N | **DAPTO**S NS N | **DOXY/MINO**S I R N | **ERYTH**S I R N | **GENT**S I R N | **LNZ**S R N |
| **OX/CEFOX/METH**S I R N | **RIF**S I R N | **TETRA**S I R N | **TIG**S NS N | **TMZ**S I R N | **VANC**S I R N | **CEFTAR**S S-DD I R |
| Pathogen # | **Gram-negative Organisms** |
| \_\_\_\_\_\_\_ | *Acinetobacter* (specify species)\_\_\_\_\_\_\_\_\_\_\_\_ | **AMK**S I R N | **AMPSUL**S I R N | **AZT**S I R N | **CEFEP**S I R N | **CEFTAZ/CEFOT/CEFTRX**S I R N | **CIPRO/LEVO**S I R N | **COL/PB**S I R N |
| **GENT**S I R N | **IMI**S I R N | **MERO/DORI**S I R N | **PIP/PIPTAZ**S I R N | **TETRA/DOXY/MINO**S I R N |  |
| **TMZ**S I R N | **TOBRA**S I R N |  |
| \_\_\_\_\_\_\_ | *Escherichia coli* | **AMK**S I R N | **AMP**S I R N | **AMPSUL/AMXCLV**S I R N | **AZT**S I R N | **CEFAZ**S I R N | **CEFEP**S I/S-DD R N | **CEFOT/CEFTRX**S I R N |
| **CEFTAZ**S I R N | **CEFUR**S I R N | **CEFOX/CTET****S I R N** | **CEFTAVI**S R N | **CEFTOTAZ**S I R N | **CIPRO/LEVO/MOXI**S I R N | **COL/PB†**S I R N |
| **ERTA**S I R N | **GENT**S I R N | **IMI**S I R N | **MERO/DORI**S I R N | **PIPTAZ**S I R N | **TETRA/DOXY/MINO**S I R N |
| **TIG**S I R N | **TMZ**S I R N | **TOBRA**S I R N | **IMIREL****S I R N** | **MERVAB****S I R N** |  |  |
| \_\_\_\_\_\_\_ | *Enterobacter* (specify species)\_\_\_\_\_\_\_\_\_\_\_\_ | **AMK**S I R N | **AMP**S I R N | **AMPSUL/AMXCLV**S I R N | **AZT**S I R N | **CEFAZ**S I R N | **CEFEP**S I/S-DD R N | **CEFOT/CEFTRX**S I R N |
| **CEFTAZ**S I R N | **CEFUR**S I R N | **CEFOX/CTET**S I R N | **CIPRO/LEVO/MOXI**S I R N | **COL/PB**S I R N | **CEFTAVI**S R N |
| **ERTA**S I R N | **GENT**S I R N | **IMI**S I R N | **MERO/DORI**S I R N | **PIPTAZ**S I R N | **TETRA/DOXY/MINO**S I R N |
| **TIG**S I R N | **TMZ**S I R N | **TOBRA**S I R N | **CEFTOTAZ****S I R N** | **IMIREL****S I R N** | **MERVAB****S I R N** |  |
| \_\_\_\_\_\_\_ | *\_\_\_\_Klebsiella* *pneumonia**\_\_\_\_Klebsiella* *oxytoca*\_\_\_*Klebsiella* *aerogenes* | **AMK**S I R N | **AMP**S I R N | **AMPSUL/AMXCLV**S I R N | **AZT**S I R N | **CEFAZ**S I R N | **CEFEP**S I/S-DD R N | **CEFOT/CEFTRX**S I R N |
| **CEFTAZ**S I R N | **CEFUR**S I R N | **CEFOX/CTET**S I R N | **CIPRO/LEVO/MOXI**S I R N | **COL/PB†**S I R N | **CEFTAVI**S R N |
| **ERTA**S I R N | **GENT**S I R N | **IMI**S I R N | **MERO/DORI**S I R N | **PIPTAZ**S I R N | **TETRA/DOXY/MINO**S I R N |
| **TIG**S I R N | **TMZ**S I R N | **TOBRA**S I R N | **CEFTOTAZ****S I R N** | **IMIREL****S I R N** | **MERVAB****S I R N** |  |

|  |  |
| --- | --- |
| Pathogen # | **Gram-negative Organisms** |
| \_\_\_\_\_\_\_ | *Pseudomonas aeruginosa* | **AMK**S I R N | **AZT**S I R N | **CEFEP**S I R N | **CEFTAZ**S I R N | **CIPRO/LEVO**S I R N | **COL/PB**S I R N | **GENT**S I R N |
|  |  | **IMI**S I R N | **MERO/DORI**S I R N | **PIP/PIPTAZ**S I R N | **CEFTAVI**S R N | **TOBRA**S I R N | **CEFTOTAZ****S I R N** |
| Pathogen # | **Fungal Organisms** |
| \_\_\_\_\_\_\_ | *Candida* (specify species if available)\_\_\_\_\_\_\_\_\_\_\_\_ | **ANID**S I R N | **CASPO**S NS N | **FLUCO**S S-DD R N | **FLUCY**S I R N | **ITRA**S S-DD R N | **MICA**S NS N | **VORI**S S-DD R N |
| Pathogen # | **Other Organisms** |
| \_\_\_\_\_\_\_ | Organism 1 (specify)\_\_\_\_\_\_\_\_\_\_\_\_ | \_\_\_\_\_\_\_Drug 1S I R N | \_\_\_\_\_\_\_ Drug 2S I R N | \_\_\_\_\_\_Drug 3S I R N | \_\_\_\_\_\_\_ Drug 4S I R N | \_\_\_\_\_\_\_Drug 5S I R N | \_\_\_\_\_\_ Drug 6S I R N | \_\_\_\_\_\_ Drug 7S I R N | \_\_\_\_\_\_ Drug 8S I R N | \_\_\_\_\_\_ Drug 9S I R N |
| \_\_\_\_\_\_\_ | Organism 1 (specify)\_\_\_\_\_\_\_\_\_\_\_\_ | \_\_\_\_\_\_\_Drug 1S I R N | \_\_\_\_\_\_\_ Drug 2S I R N | \_\_\_\_\_\_Drug 3S I R N | \_\_\_\_\_\_\_ Drug 4S I R N | \_\_\_\_\_\_\_Drug 5S I R N | \_\_\_\_\_\_ Drug 6S I R N | \_\_\_\_\_\_ Drug 7S I R N | \_\_\_\_\_\_ Drug 8S I R N | \_\_\_\_\_\_ Drug 9S I R N |
| \_\_\_\_\_\_\_ | Organism 1 (specify)\_\_\_\_\_\_\_\_\_\_\_\_ | \_\_\_\_\_\_\_Drug 1S I R N | \_\_\_\_\_\_\_ Drug 2S I R N | \_\_\_\_\_\_Drug 3S I R N | \_\_\_\_\_\_\_ Drug 4S I R N | \_\_\_\_\_\_\_Drug 5S I R N | \_\_\_\_\_\_ Drug 6S I R N | \_\_\_\_\_\_ Drug 7S I R N | \_\_\_\_\_\_ Drug 8S I R N | \_\_\_\_\_\_ Drug 9S I R N |

**Result Codes**

**S = Susceptible I = Intermediate R = Resistant NS = Non-susceptible S-DD = Susceptible-dose dependent N = Not tested**

**§ GENTHL results: S = Susceptible/Synergistic and R = Resistant/Not Synergistic**

**† Clinical breakpoints have not been set by FDA or CLSI, Sensitive and Resistant designations should be based upon epidemiological cutoffs of Sensitive MIC ≤ 2 and Resistant MIC ≥ 4**

| **Drug Codes:** |  |  |  |
| --- | --- | --- | --- |
| AMK = amikacin | CEFTOTAZ = ceftolozane/tazobactam | FLUCY = flucytosine | OX = oxacillin |
| AMP = ampicillin | GENT = gentamicin | PB = polymyxin B |
| AMPSUL = ampicillin/sulbactam | CEFTRX = ceftriaxone  | GENTHL = gentamicin –high level test | PIP = piperacillin |
| AMXCLV = amoxicillin/clavulanic acid | CEFUR= cefuroxime | IMI = imipenem | PIPTAZ = piperacillin/tazobactam |
| ANID = anidulafungin | CTET= cefotetan | IMIREL= imipenem/relebactam | RIF = rifampin |
| AZT = aztreonam | CIPRO = ciprofloxacin | ITRA = itraconazole | TETRA = tetracycline |
| CASPO = caspofungin | CLIND = clindamycin | LEVO = levofloxacin | TIG = tigecycline |
| CEFAZ= cefazolin | COL = colistin | LNZ = linezolid  | TMZ = trimethoprim/sulfamethoxazole |
| CEFEP = cefepime | DAPTO = daptomycin | MERO = meropenem |
| CEFOT = cefotaxime | DORI = doripenem | MERVAB= meropenem/vaborbactam | TOBRA = tobramycin |
| CEFOX= cefoxitin | DOXY = doxycycline  | METH = methicillin |  |
| CEFTAR = Ceftaroline | ERTA = ertapenem | MICA = micafungin | VANC = vancomycin |
| CEFTAVI = ceftazidime/avibactam | ERYTH = erythromycin | MINO = minocycline | VORI = voriconazole |
| CEFTAZ = ceftazidime | FLUCO = fluconazole | MOXI = moxifloxacin |  |
|  |  |  |  |

|  |
| --- |
| **Custom Fields** |
| Label | Label |
|  |  |
| \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_ | \_\_\_\_/\_\_\_\_/\_\_\_\_ | \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_ | \_\_\_\_/\_\_\_\_/\_\_\_\_\_ |
| \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_ | \_\_\_\_\_\_\_\_\_\_\_\_\_ | \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_ | \_\_\_\_\_\_\_\_\_\_\_\_\_\_ |
| \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_ | \_\_\_\_\_\_\_\_\_\_\_\_\_ | \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_ | \_\_\_\_\_\_\_\_\_\_\_\_\_\_ |
| \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_ | \_\_\_\_\_\_\_\_\_\_\_\_\_ | \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_ | \_\_\_\_\_\_\_\_\_\_\_\_\_\_ |
| \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_ | \_\_\_\_\_\_\_\_\_\_\_\_\_ | \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_ | \_\_\_\_\_\_\_\_\_\_\_\_\_\_ |
| \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_ | \_\_\_\_\_\_\_\_\_\_\_\_\_ | \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_ | \_\_\_\_\_\_\_\_\_\_\_\_\_\_ |
| \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_ | \_\_\_\_\_\_\_\_\_\_\_\_\_ | \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_ | \_\_\_\_\_\_\_\_\_\_\_\_\_\_ |
| **Comments** |
|  |